FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Wyeth, Elan suspend Alzheimer's vaccine study

Wyeth and Elan have suspended dosing patients in a mid-stage study of the experimental Alzheimer's vaccine ACC-001 after seeing one of the patients in the study develop skin lesions. Studies of ACC-001 that have been mounted outside of the U.S. have also been suspended. Researchers, though, quickly sought to reassure investors that another late-stage program for AAB-001 wasn't affected by the unexplained case of lesions. AAB-001, or bapineuzumab, has demonstrated an improvement in cognitive function in Alzheimer's patients in a small study and is being closely followed by the investment community.

- read the story in the Wall Street Journal
-
read the story in TheStreet.com

Related Articles:
Wyeth stumbles badly trying to develop new drugs. Wyeth report
Wyeth, Elan advance Phase III Alzheimer's trial. Alzheimer's report

More stories about Vaccines   vaccine   Wyeth   Elan   Alzheimer's   New Drugs   Phase III   AAB-001   ACC-001  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 7 + 19?
To combat spam, please solve the math question above.